A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients
NCT ID: NCT01499368
Last Updated: 2025-01-15
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
495 participants
INTERVENTIONAL
2011-11-30
2012-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis
NCT02456935
Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of the Remission Rates of Once Daily Treatment With Esomeprazole 20mg and Lansoprazole 15mg for 6 Months in Patients Whose EE Has Been Healed
NCT00644735
JP-1366 20mg Versus Esomeprazole 40mg in Patients With Erosive Esophagitis
NCT05443984
Reflux Esophagitis Phase III Study (Initial Treatment)
NCT00633932
Phase II Clinical Study of Vonorasan Fumarate Injection in the Treatment of Peptic Ulcer Bleeding
NCT06783257
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lafutidine
Lafutidine 20mg/day
Lafutidine
Lafutidine 20mg/day
Famotidine
Famotidine 40mg/day
Famotidine
Famotidine 40mg/day
Omeprazole
Omeprazole 20mg/day
Omeprazole
Omeprazole 20mg/day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lafutidine
Lafutidine 20mg/day
Famotidine
Famotidine 40mg/day
Omeprazole
Omeprazole 20mg/day
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Concurrent presence of Barrett's esophagus
* A history of a poor response to H2RA or PPI given in the recommended dose for 8 weeks
* Other conditions considered by the attending physician to potentially affect the assessment of efficacy and safety
20 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Boryung Pharmaceutical Co., Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sang Woo Lee
Role: STUDY_CHAIR
Korea University Ansan Hospital
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LAF-BR-CT-302
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.